1,639 research outputs found
Precision oncology in esophagogastric cancer:From biomarker to personalized treatment
Despite the benefits achieved through multimodality treatment, the prognosis of esophageal and gastric remains dismal. Hence, improvement of current therapeutic strategies is imperative. In this thesis, we focus on intensification of non-targeted treatment, as well as precision oncology in esophagogastric cancer with the use of targeted therapies. The results in this thesis show a lack of feasibility of administrating adjuvant chemotherapy in patients with resectable esophageal adenocarcinoma in an unselected cohort, suggesting a role for treatment intensification in the neoadjuvant setting. Moreover, our findings enable optimization of HER2 directed therapy in patients with resectable esophageal adenocarcinoma by broadening our understanding of HER2 targeting through potential interactions with the tumor immune microenvironment, unraveling resistance mechanisms, and identifying predictive biomarkers which could be used for patient stratification. Furthermore, we investigated targeting of angiogenesis through the multikinase inhibitor regorafenib in advanced gastroesophageal cancer, providing biomarkers for patient selection and suggestions for novel treatment combinations. Taken together, these findings can guide the development of novel therapeutic strategies in patients with esophagogastric cancer, ultimately aiming to improve the overall outcome of patients with esophageal and gastric cancer
Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
Background: Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCSK9 inhibition on circulating metabolites such as lipoprotein subclasses, amino acids and fatty acids remain to be characterized. Methods: We performed nuclear magnetic resonance (NMR) metabolomics on plasma samples derived from 30 individuals with elevated Lp(a) (> 150 mg/dL). The 30 participants were randomly assigned into two groups, placebo (N = 14) and evolocumab (N = 16). We assessed the effect of 16 weeks of evolocumab 420 mg Q4W treatment on circulating metabolites by running lognormal regression analyses, and compared this to placebo. Subsequently, we assessed the interrelationship between Lp(a) and 14 lipoprotein subclasses in response to treatment with evolocumab, by running multilevel multivariate regression analyses. Results: On average, evolocumab treatment for 16 weeks resulted in a 17% (95% credible interval: 8 to 26%, P < 0.001) reduction of circulating Lp(a), coupled with substantial reduction of VLDL, IDL and LDL particles as well as their lipid contents. Interestingly, increasing concentrations of baseline Lp(a) were associated with larger reduction in triglyceride-rich VLDL particles after evolocumab treatment. Conclusions: Inhibition of PCSK9 with evolocumab markedly reduced VLDL particle concentrations in addition to lowering LDL-C. The extent of reduction in VLDL particles depended on the baseline level of Lp(a). Our findings suggest a marked effect of evolocumab on VLDL metabolism in subjects with elevated Lp(a). Trial registration: Clinical trial registration information is registered at ClinicalTrials.gov on April 14, 2016 with the registration number NCT02729025.</p
Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce lowâdensity lipoprotein cholesterol (LDLâC) when added to statin therapy in patients who need additional LDLâC reduction.
Methods and Results: We conducted a systematic review and network metaâanalysis of randomized trials of lipidâlowering therapies from database inception through August 2016 (45 058 records retrieved). We found 69 trials of lipidâlowering therapies that enrolled patients requiring further LDLâC reduction while on maximally tolerated mediumâ or highâintensity statin, of which 15 could be relevant for inclusion in LDLâC reduction networks with evolocumab, alirocumab, ezetimibe, and placebo as treatment arms. PCSK9 inhibitors significantly reduced LDLâC by 54% to 74% versus placebo and 26% to 46% versus ezetimibe. There were significant treatment differences for evolocumab 140 mg every 2 weeks at the mean of weeks 10 and 12 versus placebo (â74.1%; 95% credible interval â79.81% to â68.58%), alirocumab 75 mg (â20.03%; 95% credible interval â27.32% to â12.96%), and alirocumab 150 mg (â13.63%; 95% credible interval â22.43% to â5.33%) at â„12 weeks. Treatment differences were similar in direction and magnitude for PCSK9 inhibitor monthly dosing. Adverse events were similar between PCSK9 inhibitors and control. Rates of adverse events were similar between PCSK9 inhibitors versus placebo or ezetimibe.
Conclusions: PCSK9 inhibitors added to mediumâ to highâintensity statin therapy significantly reduce LDLâC in patients requiring further LDLâC reduction. The network metaâanalysis showed a significant treatment difference in LDLâC reduction for evolocumab versus alirocumab
Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice
F.B. is supported by Swedish Research Council, Swedish Diabetes Foundation, Swedish Heart Lung Foundation, Swedish Foundation for Strategic Research, Knut and Alice Wallenberg foundation, Göran Gustafsson Foundation, Ingbritt and Arne Lundbergâs foundation, Swedish Heart Lung Foundation, Torsten Söderbergâs Foundation, Ragnar Söderbergâs Foundation, NovoNordisk Foundation, AFA insurances, and LUA-ALF grants from VĂ€stra Götalandsregionen and Stockholm County Council. F.B. is a recipient of ERC Consolidator Grant (European Research Council, Consolidator grant 615362âMETABASE). W.M.d.V. is supported by the Finland Academy of Sciences (grants 137389, 141140 and 1272870 ), the Netherlands Organization for Scientific Research (Spinoza Award and SIAM Gravity Grant 024.002.002) and the European Research Council (ERC Advanced Grant 250172 MicrobesInside). M.N. is supported by a ZONMW-VIDI grant 2013 (016.146.327).Peer reviewedPublisher PD
- âŠ